Avanir CEO heads for the exit after stock plunge

Just days after seeing Avanir's share price plunge 51 percent on the FDA's insistence for a new trial for Zenvia, a therapy for involuntary emotional expression disorder, company CEO Eric K. Brandt has resigned. Keith A. Katkin, senior vice president of sales and marketing, took his place. Company director Craig Wheeler said that Katkin's "contributions to the company have been meaningful, and the board anticipates that Keith will continue to show his considerable leadership skills as he navigates the company toward the anticipated eventual approval of Zenvia for IEED and minimizes operating expenses during this time."

- check out Anavir's release
- here's the report from the Orange County Register

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.